Načítá se...
Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis
OBJECTIVE: To assess safety outcomes for the induction therapies alemtuzumab and autologous hematopoietic stem cell transplantation (AHSCT) compared to noninduction disease-modifying therapies. METHODS: We performed a population-based cohort study linking the Swedish Multiple Sclerosis Register to n...
Uloženo v:
| Vydáno v: | Neurology |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Lippincott Williams & Wilkins
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8032381/ https://ncbi.nlm.nih.gov/pubmed/33514645 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000011545 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|